Catalys Pacific, LLC has made significant moves in the biotechnology sector, as revealed in its recent filing. The company reported its holdings in two biotech firms, Mineralys Therapeutics and Phathom Pharmaceuticals, in a 13F-HR filing dated October 30, 2026. This update is crucial as it showcases Catalys's strategic investment choices and its commitment to the growing biotech industry.

Catalys Pacific, LLC is an investment firm based in Tokyo, Japan. It operates under the Central Index Key (CIK) number 0002011385 and is categorized as an 'other' entity type. The firm has been active in filing various reports, including multiple 13F-HR forms throughout 2026, reflecting its ongoing investment activities.

The latest filing indicates that Catalys Pacific holds a total value of approximately $209.7 million in its reported investments. Specifically, the firm has invested $196 million in Mineralys Therapeutics, holding nearly 7.8 million shares, and $13.7 million in Phathom Pharmaceuticals, with over 1.8 million shares. The filing states, "Investment discretion is sole," indicating that Catalys has full control over these investments.

This filing may impact various stakeholders, including investors, market analysts, and competitors within the biotechnology sector. The decision to invest heavily in these companies aligns with a broader trend of increasing interest in biotech solutions, particularly in the wake of recent healthcare advancements.

As for what comes next, the filing does not specify any forthcoming actions or additional filings. However, the ongoing monitoring of these investments will be crucial for stakeholders looking to assess Catalys's future strategies in the biotech market.